La French Touch: How France Has Built a Reputation for Excellence In Medtech

France’s medtech sector is strong, growing and innovative. In Vivo spoke to several French medtech leaders about the unique features and pitfalls their industry may face.

Through the combination of a comparatively strong economy, a highly skilled, motivated workforce, and a generous tax system, France is quickly developing a reputation for being one of the best places to invent, develop and subsequently commercialize medical devices.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By 

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal

 
• By 

Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.

Barcelona Health Hub: Where Digital Health Innovation Meets Historic Art Nouveau

 
• By 

The Barcelona Health Hub is a nonprofit that seeks to advance digital health innovation by bringing together start-ups, investors, health care institutions and corporations.

Reinventing Prevention: Milken Institute Foresees Another Route Using Private And Public Funding

 
• By 

New funding mechanisms are required to give more momentum to prevention in the community and thereby relieve pressure on overburdened health care providers like the UK National Health Service. So says Simon Radford, a director at global thinktank the Milken Institute, which sees a solution in more funding for community-level prevention.

More from Market Intelligence

Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing

 
• By 

Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.

Mirum’s Rare Disease Strategy: A Blueprint For Sustainable Growth

 
• By 

From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.